NEUROLOGY UPDATE  |  ALZHEIMER'S DISEASE & DEMENTIA CARE

June 2026  |  NP Chronicles Clinical Education

 

Glucosamine and Alzheimer's Disease: What a Landmark Nature Metabolism Study Means for Your Patients Right Now

By Valerie Watters-Burke, DNSc, MSN, MBA, FNP-BC, GNP-BC, PPCNP-BC

Based on: Hawkinson TR, Liu Z, et al. Hyperglycosylation is a metabolic driver of Alzheimer's disease. Nature Metabolism. 2026. doi:10.1038/s42255-026-01538-4

 

CLINICAL BOTTOM LINE

⚠ CLINICAL SAFETY ALERT: A major study published in Nature Metabolism (June 2026) found that glucosamine supplementation — one of the most widely used OTC joint health supplements — is associated with a 25% increase in mortality in patients with Alzheimer's disease-related dementia (ADRD), and a 25% increase in MCI-to-AD conversion rates. The biological mechanism is now well-characterized: glucosamine feeds the hexosamine biosynthetic pathway, driving brain hyperglycosylation that is a causal driver of AD progression. This is not a theoretical risk. It is actionable today, in your next clinical encounter.

 

Why This Is Not Just Another Observational Study

Every week, new papers report associations between supplements and health outcomes. Most NPs have learned to hold these findings loosely — correlation, confounding, publication bias, small samples. This paper deserves a different level of attention, for reasons that go beyond the headline finding.

This study provides both a mechanism and a clinical signal — simultaneously. The researchers at the University of Florida did not merely find that glucosamine users with dementia do worse. They demonstrated, through an integrated chain of evidence, exactly why that happens — at the molecular level — and then confirmed the effect in human EHR data from over 50,000 patients. That combination is unusual and important.

The convergent evidence includes:

1.    Spatial multiomics in human post-mortem AD brain tissue (n=3 matched pairs) demonstrating dramatically elevated glycan abundance across both grey and white matter in AD vs. normal brains

2.    Braak stage-stratified analysis in FFPE human samples showing that glycan accumulation increases progressively with AD severity — more glycosylation at Braak 5-6 than at Braak 0

3.    Replication in two independent, mechanistically distinct transgenic mouse models: 5xFAD (amyloid-driven) and PS19 (tau-driven), showing the same hyperglycosylation phenotype in both

4.    Stable isotope pulse-chase tracing proving the mechanism is increased glycan biosynthesis — not decreased degradation

5.    Genetic knockdown of glycan biosynthesis enzymes (PGM3) improving social memory in AD mice

6.    Oral glucosamine supplementation worsening memory in AD mice without changing amyloid plaque burden

7.    Retrospective EHR analysis of 66,000+ patients showing glucosamine use linked to 25% increased mortality in ADRD and 25% increased MCI-to-ADRD conversion

 

Each piece of this puzzle is independently compelling. Together, they make a case for causality, not just correlation.

The Science: Hyperglycosylation as a Disease Driver

Let's build a working mental model of what this paper found, because understanding the mechanism will help you explain it to patients and colleagues — and will serve you well as this research moves toward clinical translation.

What Are N-Linked Glycans?

Glycosylation is a post-translational modification — meaning it happens after a protein is synthesized. In N-linked glycosylation, sugar chains (glycans) are attached to nitrogen atoms on specific asparagine residues of proteins. This is not a minor biochemical footnote. N-linked glycosylation is essential for:

•       Protein folding and stability in the endoplasmic reticulum

•       Intracellular trafficking — getting proteins to the right location in the cell

•       Receptor-ligand interactions at the cell surface

•       Synaptic plasticity and neurotransmitter receptor function

•       Neuroimmune signaling and blood-brain barrier integrity

 

In the brain specifically, glycosylation is intimately involved in how neurons communicate, how microglia function, and how tau protein is processed and aggregated. If glycosylation goes wrong, multiple AD pathological processes are affected simultaneously.

What Is Hyperglycosylation and Why Does It Happen in AD?

Hyperglycosylation means the brain is producing too many glycans — not just different glycans, but a dramatic quantitative overabundance of N-linked glycan structures attached to neuronal membrane proteins.

The study showed this was driven by increased biosynthesis through the hexosamine biosynthetic pathway — not by impaired glycan recycling or degradation. Using 13C-labeled glucose and pulse-chase experiments, the researchers tracked glycan production in real time and found that AD brains were manufacturing glycans at a significantly higher rate than wild-type controls.

The mechanism looks like this:

Glucose → Glucosamine-6-phosphate → N-acetylglucosamine (GlcNAc) → UDP-GlcNAc → N-linked glycan biosynthesis in the ER/Golgi apparatus

In AD brains: this pathway is upregulated. More glycans are made. They accumulate on neuronal membrane proteins — particularly proteins involved in synaptic function and signal transduction.

The result: hyperglycosylated neurons that are functionally compromised even before classic AD hallmarks (plaques and tangles) become severe.

 

One particularly important finding: even though UDP-GlcNAc (the shared precursor) is elevated in AD brains, hyaluronic acid production and O-GlcNAcylation — two other pathways that draw from the same UDP-GlcNAc pool — are actually decreased. This means AD brains are selectively channeling the hexosamine pathway toward N-linked glycosylation at the expense of other downstream processes. This is a specific metabolic reprogramming, not a generalized increase in hexosamine activity.

Is Hyperglycosylation Cause or Consequence?

This is the critical question — and the study addressed it directly through genetic and dietary interventions.

Evidence that hyperglycosylation is causal:

•       When PGM3 (a key enzyme in the hexosamine pathway) was knocked down using shRNA in AD mice, brain glycan levels decreased AND social memory improved. The memory benefit occurred without any change in amyloid plaque count or reactive astrocyte levels — suggesting glycosylation operates as an independent pathological driver.

•       When NGI-1 (a small-molecule inhibitor of the oligosaccharyltransferase complex that performs N-linked glycosylation) was administered, the same result: reduced glycans, improved memory in AD mice.

•       Critically, when PGM3 was knocked down in healthy wild-type mice, memory was not impaired. This indicates that targeting the pathway in a diseased brain reduces pathological excess without harming normal glycosylation function.

•       Glucosamine supplementation in AD mice increased brain glycosylation and worsened social memory — a direct pharmacologic confirmation of the pathway's role.

 

The evidence for a causal role is unusually strong for a study of this type. This is not a biomarker association — it is a mechanism-function relationship supported by multiple independent lines of experimental evidence.

The Glucosamine Data: What the EHR Analysis Found

The Study Population

The researchers analyzed electronic health records from the University of Florida Health system — one of the largest academic health systems in the southeastern United States. They identified over 50,000 patients with diagnoses of AD, Alzheimer's disease-related dementia (ADRD), or mild cognitive impairment (MCI). Glucosamine users were identified through physician notes and prescription records using natural language processing, with users defined as those with documented glucosamine use for at least one year following diagnosis.

The final survival analysis included 24,481 patients with ADRD and 41,884 patients with MCI. Median follow-up was approximately 5 years. Propensity score matching was used to control for age, sex, and demographics.

Key Findings

Glucosamine use in ADRD patients: 25% increase in all-cause mortality (P = 0.0023)

Glucosamine use in MCI patients: No significant mortality increase (P = 0.252)

Glucosamine use in MCI patients: 25% increase in conversion from MCI to ADRD (P < 0.001)

Across all three diagnostic categories, approximately 8% of patients had documented glucosamine use

 

The MCI-to-ADRD Conversion Finding Is Clinically Critical

The differential effect between MCI and ADRD is one of the most important nuances in this paper. Glucosamine did not increase mortality in the MCI cohort — but it did significantly accelerate the transition from MCI to full dementia. This is consistent with the animal model data, which showed that glucosamine supplementation in healthy wild-type mice did not cause hyperglycosylation or cognitive impairment.

The researchers propose that this pattern reflects a threshold effect: the AD brain has already lost its normal regulatory mechanisms for glycan homeostasis. Once that metabolic vulnerability is established, exogenous glucosamine can push the dysregulated pathway further, accelerating disease. The non-demented or mildly impaired brain, with its metabolic compensatory mechanisms intact, can handle glucosamine without the same consequences.

Clinical implication: A patient taking glucosamine who is later diagnosed with MCI or ADRD has an ongoing exposure that may be accelerating their cognitive trajectory. The time to address this is not after they progress to full dementia — it is at the MCI stage, when intervention may still change the course of disease.

 

Scale of the Problem

Approximately 8% of patients with AD or ADRD in this academic health system had documented glucosamine use. The study authors extrapolate that with 6.7 million Americans living with AD and another 7 million with ADRD, over 1 million people may be currently using glucosamine in a way that is unknowingly accelerating their neurodegeneration.

This is not a rare exposure. Glucosamine is widely available without a prescription, is heavily marketed for joint and cartilage health, and is commonly recommended by lay sources and some clinicians for osteoarthritis management. Many of your older patients with cognitive impairment are taking it.

What This Means for Your Clinical Practice

1. Glucosamine Is Now a Contraindicated Supplement in Patients With Established AD or ADRD

This is the most direct clinical takeaway. In patients with a confirmed diagnosis of Alzheimer's disease or any Alzheimer's disease-related dementia, glucosamine supplementation should be discontinued and is not recommended. The evidence for harm is sufficiently robust — mechanistically grounded, replicated across two animal models, and confirmed in a large human EHR cohort — to justify a clear clinical recommendation.

This conversation needs to happen actively. Patients and families often assume that because a supplement is available without a prescription, it is safe. They may not have told any of their dementia care providers that they are taking it. You need to ask.

2. For MCI Patients: Discuss Risk and Recommend Discontinuation

The MCI finding is more nuanced but equally actionable. Glucosamine did not increase mortality in the MCI cohort, but it did significantly increase the rate of progression to ADRD. Given that delaying progression from MCI to dementia is one of the primary goals of MCI management, this is a clinically meaningful harm.

For patients with MCI who are taking glucosamine, the risk-benefit calculation has shifted substantially. The evidence for glucosamine's benefit in osteoarthritis is itself modest and contested — the GAIT trial and subsequent meta-analyses showed inconsistent results, and most guidelines do not strongly endorse it. Weighing uncertain joint health benefit against a 25% increase in conversion to dementia leads to a straightforward recommendation: stop the glucosamine.

There are alternative approaches to joint pain management in older adults that carry no theoretical AD risk: topical NSAIDs, acetaminophen (appropriately dosed), physical therapy, weight optimization, omega-3 (with appropriate attention to anticoagulation status), and for appropriate candidates, intra-articular interventions.

3. Distinguish Glucosamine from Chondroitin

Many joint health supplement products combine glucosamine with chondroitin sulfate. This study specifically implicates glucosamine — not chondroitin — because glucosamine is the direct substrate for the hexosamine biosynthetic pathway and can cross the blood-brain barrier, directly incorporating into brain glycans. Chondroitin has a different metabolic profile and was not implicated in this research. That said, the combination products should still prompt discontinuation of the glucosamine component.

4. Build Supplement Review Into Cognitive Impairment Encounters

Supplement review is not a standard part of most dementia evaluation templates. This research suggests it should be. When you are seeing a patient for cognitive concerns — whether initial evaluation, MCI follow-up, or dementia management — supplement review needs to be explicit and include glucosamine specifically.

Suggested language: "I want to review everything you take for your joints, inflammation, or general health — including any over-the-counter supplements. There's some important new research I want to discuss with you about one of the most common joint supplements."

 

5. Counsel Families and Caregivers

In dementia care, the patient's family or primary caregiver is often managing the medication and supplement regimen. The patient may not know what they are taking. The caregiver needs to hear this information and understand why it matters. Consider including a brief note in your after-visit summary that explicitly lists glucosamine as a supplement to avoid in the context of the patient's cognitive diagnosis.

6. Consider the Broader Supplement Picture

The hexosamine pathway substrate is N-acetylglucosamine (GlcNAc). In addition to glucosamine, N-acetylglucosamine is sold as a standalone supplement (marketed for gut health, skin health, and joint support). The same mechanistic concern applies — this supplement directly feeds the pathway implicated in brain hyperglycosylation. It should be treated with the same clinical caution in patients with AD or MCI.

Other supplements marketed for joint or cartilage health that are not glucosamine (turmeric/curcumin for anti-inflammatory effects, collagen peptides, MSM) do not share this mechanism and are not implicated by this research.

Understanding the Technology: How Researchers Mapped This

One reason this paper is methodologically significant is the use of MALDI-MSI (matrix-assisted laser desorption/ionization mass spectrometry imaging) — a technique that allows spatial mapping of metabolites, lipids, and glycans directly on brain tissue sections, preserving their anatomical location. Think of it as a molecular photograph of the brain's chemistry at the tissue level.

By applying this technology across multiple brain regions and Braak stages, and then adding stable isotope pulse-chase tracing (feeding 13C-labeled glucose and tracking its incorporation into glycan structures over time), the researchers could see not just where glycans were accumulating, but how quickly they were being made and how slowly they were being turned over. The increased 13C enrichment in AD mouse brains during the pulse phase — without any difference in the chase phase — proved definitively that the driver was overproduction, not underrecycling.

This level of metabolic resolution in intact brain tissue is a methodological advance. As spatial multiomics tools become more available in research and eventually clinical settings, they will open new windows into the metabolic underpinnings of neurodegeneration.

What This Study Does Not Tell Us — Maintaining Scientific Rigor

NPs should be able to discuss the limitations of this research as fluently as its findings. This is what good clinical reasoning looks like.

•       The EHR cohort is retrospective and observational. Propensity score matching reduces but does not eliminate confounding. Patients who use glucosamine may differ from non-users in ways the matching did not capture — health consciousness, supplement polypharmacy, socioeconomic factors, or access to care.

•       The EHR-based glucosamine identification relied on physician notes and NLP extraction — not a randomized drug assignment. Documentation bias and inconsistent note-taking could affect who was classified as a glucosamine user.

•       The human brain tissue studies involved small sample sizes (n=3 per group), which is a limitation acknowledged by the authors. The mouse model data had similarly small n values. The EHR analysis provides the large-sample human confirmation.

•       We do not yet know the threshold of glucosamine exposure that matters — dose, duration, formulation, or route may all be relevant. The study does not provide dosing guidance.

•       The study authors appropriately call for a large-scale, double-blind clinical trial to definitively establish causation and quantify the dose-response relationship. That trial has not yet been conducted.

 

None of these limitations undermine the clinical recommendation to discontinue glucosamine in patients with established AD or ADRD. The convergence of mechanistic, animal, and large-scale human evidence is sufficient to justify the conversation — and the risk of continued use outweighs any proven benefit.

The Therapeutic Horizon: What's Coming

This research opens a genuinely new therapeutic avenue for AD that is distinct from the amyloid-targeting approaches that have dominated the field for decades. The authors identify two promising intervention strategies:

Enzyme Inhibition: Targeting PGM3 or OST

Phosphoglucomutase 3 (PGM3) is the enzyme that converts glucosamine-6-phosphate to N-acetylglucosamine-6-phosphate — a critical step in the hexosamine pathway. Oligosaccharyltransferase (OST) is the enzyme complex that performs the actual glycan transfer to nascent proteins in the ER. Both are druggable targets.

The study showed that genetic knockdown of PGM3 and pharmacologic inhibition of OST (using NGI-1) both reduced brain glycosylation and improved social memory in AD mice, without altering amyloid plaque burden or neuroinflammatory markers. This suggests that glycan-targeted therapy could be additive or complementary to amyloid-clearing approaches like lecanemab (Leqembi) or donanemab.

The key barrier to translation is blood-brain barrier permeability. Currently available PGM3 inhibitors do not cross the BBB in sufficient concentrations. This is an active research priority.

Dietary Intervention: Reducing Hexosamine Pathway Substrate

If the hexosamine pathway is upregulated in AD, dietary strategies that reduce substrate availability could theoretically reduce glycan overproduction. This is more complex than simply avoiding glucosamine supplements — dietary glucose is the primary upstream substrate. The relationship between blood glucose control, glucose uptake in the AD brain (already reduced as shown on FDG-PET), and glycan biosynthesis is likely nuanced. Hyperglycemia may paradoxically feed the hexosamine pathway even as neurons are glucose-starved for energy production.

For now, the practical dietary recommendation is straightforward: stop supplemental glucosamine and N-acetylglucosamine in patients with AD or MCI. Broader dietary strategies targeting the hexosamine pathway await further research.

 

Connecting the Dots: Supplements and Older Patients

If you read the companion NP Chronicles post on the JAMA Network Open supplement trend data, you know that nearly 80% of Americans over 65 are using dietary supplements — and that supplement use has diversified dramatically beyond multivitamins toward targeted products marketed for joint, gut, immune, and anti-inflammatory health.

Glucosamine sits squarely in that joint health category. It is one of the most commonly used supplements in the older adult population — the same population with the highest rates of cognitive impairment. The intersection of these two realities creates an urgent clinical problem that NPs are uniquely positioned to address.

You are often the provider who knows your patients' supplement regimens most completely — because you ask, because you have longitudinal relationships, and because you approach the whole patient rather than a single organ system. That comprehensive view is exactly what is needed here.

 

For NP Students and Board Prep

This research connects several concepts that are testable for AANP and ANCC board certification:

8.    Alzheimer's disease pathophysiology: Know the classical hallmarks (amyloid plaques, neurofibrillary tau tangles, neuronal loss) and recognize that metabolic mechanisms are an emerging area of AD research.

9.    Post-translational modifications: N-linked glycosylation is a testable concept in pharmacology and cellular biology. Understanding that proteins are modified after translation — affecting their folding, stability, and function — is foundational.

10. Supplement counseling in older adults: Drug-supplement interactions and supplement safety in complex patients are recurring board themes. The glucosamine-AD relationship is a high-yield emerging example.

11. MCI vs. dementia: Know the distinction. MCI involves measurable cognitive decline without functional impairment in daily activities. Conversion to ADRD represents a clinically significant threshold — and reducing that conversion rate is a treatment goal.

12. Hexosamine pathway: While you do not need deep biochemistry for boards, understanding that glucosamine is a direct substrate for sugar biosynthesis pathways and can be incorporated into cellular structures across the body — including the brain — is the conceptual foundation for this clinical concern.

 

The Bottom Line for Practice

Alzheimer's disease research has spent decades focused on amyloid and tau. This paper opens a new chapter by establishing hyperglycosylation — driven by a dysregulated metabolic pathway that glucosamine supplementation can feed — as a causal driver of neurodegeneration.

The clinical action item is immediate and straightforward: ask your patients with dementia or MCI whether they are taking glucosamine. If they are, explain the new evidence and recommend discontinuation. Document the conversation and the rationale.

The therapeutic implications are more complex and will unfold over years as the field develops PGM3 inhibitors and other glycan-targeted interventions. But the first step — removing a modifiable factor that is feeding the diseased pathway — is something you can do today, in your next encounter.

The supplement that looked like it was helping their knees may have been quietly accelerating their cognitive decline. NPs who know this can change that trajectory.

 

 

References

•       Hawkinson TR, Liu Z, Ribas RA, et al. Hyperglycosylation is a metabolic driver of Alzheimer's disease. Nature Metabolism. 2026. doi:10.1038/s42255-026-01538-4

•       Reiman EM et al. FDG-PET brain imaging in Alzheimer's disease biomarker studies. Neurology. 2012.

•       Clegg DO, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis (GAIT trial). N Engl J Med. 2006;354:795–808.

•       Rajagopal S et al. Lecanemab for early Alzheimer's disease. N Engl J Med. 2023.

•       Minhas PS et al. Restoring hippocampal glucose metabolism rescues cognition across Alzheimer's disease pathologies. Science. 2024;385:eabm6131.

•       Freeze HH et al. Neurological aspects of human glycosylation disorders. Annu Rev Neurosci. 2015;38:105–125.

 

© 2026 NP Chronicles | Clinical Education for NP Students and New Graduates | npchronicles.com

This post is intended for educational purposes. Always consult current clinical guidelines and evidence-based references for individualized patient care decisions.